La Jolla Pharmaceutical Company Is A Biopharmaceutical Firm Based In San Diegocaliforniafounded In 1989The Company Focuses On Discoveringdevelopingand Commercializing Therapies For Life Threatening Diseasesparticularly In Critical Care And Conditions Related To Severe Infections Or Metabolic Dysregulationacquired By Innoviva In August 2022La Jolla Has A Strong Commitment To Innovative Treatments For High Mortality Conditions The Company Has Conducted Over 70 Clinical Trials And Has More Than 30 Drugs In Its Development Pipelinekey Products Include Ljpc 501A Formulation For Treating Catecholamine Resistant Hypotensionand Ljpc 401Designed For Iron Overload Disordersla Jolla Also Develops Next Generation Antibiotic Therapies For Complicated Infectionswith A Robust Patent Portfolio Of 35 Patentsthe Company Is Well Positioned In The Critical Care Biopharmaceutical Markettargeting Healthcare Providers And Patients In Need Of Specialized Treatments
